Kazia inks clinical pact with Dana-Farber Cancer Institute for its lead asset in primary CNS lymphoma

Sep. 22, 2020 11:35 AM ETKazia Therapeutics Limited (KZIA)KZIABy: Vandana Singh, SA News Editor4 Comments
  • Kazia Therapeutics (KZIA +0.9%) has collaborated with Dana-Farber Cancer Institute (DFCI), to investigate its lead drug, paxalisib (formerly GDC-0084), in primary central nervous system (PCNSL) lymphoma, a potential new indication for the drug.
  • DFCI will initiate an open-label Phase 2 trial of paxalisib in PCNSL, and expects to recruit up to 25 patients, taking up to 2 years to complete. This trial will be sixth ongoing trial of paxalisib in brain cancer.
  • Kazia will provide support including study drug and a financial grant.

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.